Cellestia enters clinical development for its lead compound CB-103, a new mode of action anticancer drug targeting NOTCH positive cancers, with receiving full approval of its first-in-human Phase I – IIa clinical study.
SBA Member, 17.08.2017
Cellestia announced today the full approval of clinical trial application for CB-103 Phase I-lla first-inhuman clinical trial in patients with advanced solid cancers and haematological malignancies. CB-103 is a first-in-class oral pan-NOTCH inhibitor with a novel mode of action selectively blocking gene transcription related to NOTCH pathway activation. The trial has been approved by Competent Authority and Ethics Committee in Spain.
Clinerion announces a new technology for patient identification using fully anonymized electronic patient data.
SBA Member, 17.08.2017
- “Anonymized identification” is based on fully anonymized patient records, with no use of pseudo IDs.
- PCT patent filed for a new technology which uses a combination of techniques, incl. checksum algorithms to match anonymized records with corresponding hospital medical records.
- New system set-up increases data security and privacy protection.
- Technology can be applied in the identification of clinical trial candidate patients within trial sites.
H1 2017: Tecan with significant increase in order entry and strong sales growth in the Life Sciences Business
Clariant AG: HuntsmanClariant Deal Continues to Move Forward: Narrow "Second Request" for Additional Information Received from Federal Trade Commission
ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update
Tel Aviv University announces COLLABORATION with Biosynth on pioneering chemiluminescent reporter molecules
SBA Member, 15.08.2017
STAAD, SWITZERLAND and TEL AVIV, ISRAEL, AUGUST 14, 2017 – Biosynth, a global company supplying intermediate chemicals to the life science industry and Tel Aviv University (TAU) through Ramot its Business Engagement Center, announce the signing of a licensing agreement giving Biosynth the right to manufacture and sell probes invented by Prof. Doron Shabat from the TAU School of Chemistry.
Newly Launched Vicarius Pharma Secures CHF21 Million Financing
Business Wire, 14.08.2017
Vicarius Pharma AG, a newly-launched company providing U.S.-based bio-pharmaceutical companies a novel approach to commercializing their first asset in European markets, has secured a CHF21 million ($21.8 million) investment through a Series A preferred stock financing from private investors.
Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs
SBA Member, 10.08.2017
Completed license agreement with Pfizer for Cresemba in Europe (excluding Nordics), Russia, Turkey and Israel; CHF 70 million upfront payment and up to USD 427 million in milestones
56 percent increase in total revenue, amounting to CHF 46.2 million
BARDA committed USD 54.8 million in additional funding to support phase 3 development of ceftobiprole for registration in the U.S.
AC IMMUNE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS
SBA Member, 10.08.2017
Strong cash position of CHF 124.2 million provides resources to advance pipeline of seven therapeutic and three diagnostic candidates
Increased R&D investment across three pillars of Alzheimer`s disease, neuro-orphan indications and diagnostics
Entered into first Asian collaboration for neurodegenerative diseases and neuroinflammation with Essex Bio-Technology
VIFOR PHARMA REPORTS STRONG H1 2017 RESULTS AND RAISES GUIDANCE
ObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017
SwissBioLab bietet ein natürliches Heilmittel über die Sommermonate an, um die Nebenwirkungen von zu viel Alkohol- und Nahrungsmittelkonsum zu lindern
Business Wire, 07.08.2017
Um die Festlichkeiten in vollen Zügen zu genießen und nicht den Nachteilen zu erliegen, arbeiten zwei Schweizer Unternehmer mit Hochdruck an der Forschung und Entwicklung eines Heilmittels, das die ungewünschten Symptome, die mit einem übermäßigen Alkohol- und Nahrungsmittelkonsum zusammenhängen, wirksam bekämpft.
Idorsia announces half year results for 2017 - successful start of new biopharmaceutical company
Saphetor and Supratech Leverage Genome Scale Analyses to Facilitate Precision Oncology Treatments
Business Wire, 03.08.2017
Saphetor SA, the Swiss precision-medicine company dedicated to advancing personalized diagnostics, announced today that it will provide its proprietary platform for analyzing next-generation DNA sequencing data to Supratech Micropath (Ahmedabad, India), a reference and diagnostic lab with significant experience in clinical next-generation (NGS) DNA sequencing.
Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
Başkent University joins Clinerion’s Patient Recruitment System Platform.
SBA Member, 02.08.2017
Basel, August 2, 2017 – Başkent University’s hospital cluster is joining the Patient Recruitment System platform, giving their 4.5 M patients access to innovative treatments and therapies offered by cutting edge clinical research.
Galderma Announces Enrollment of First Patient in Phase IIb Nemolizumab Trial in Atopic Dermatitis
Lausanne – July 25, 2017– Galderma announced today the enrollment of the first patient in a multicenter double-blind Phase IIb clinical trial to evaluate nemolizumab, its investigational subcutaneous anti-IL-31 receptor A (RA) monoclonal antibody, in patients with atopic dermatitis (AD). The trial is designed to assess the efficacy of nemolizumab in moderate-to-severe AD subjects with severe pruritus receiving topical corticosteroids, who were not adequately controlled with topical treatments.
Newron Valuation Report “Persistence beats resistance” - Xadago approved in the US; positive evenamide POC
SBA Member, 07.06.2017